Nabriva Therapeutics Appoints Daniel Dolan as Chief Financial Officer
DUBLIN, Ireland and KING OF PRUSSIA, Pa., Feb. 26, 2021 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical...
Day: February 26, 2021
Oncology Pharma Signs Worldwide Licensing Agreement with Sybleu, Inc. for Commercialization of Chemotherapeutic Agent in Combination with a Bioactive Immunostimulatory Agent
San Francisco, CA, Feb. 26, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire -- Oncology Pharma Inc. (OTC: ONPH) is pleased to announce...
Molecular Templates to Participate in Upcoming Virtual Investor Conferences
AUSTIN, Texas, Feb. 26, 2021 (GLOBE NEWSWIRE) -- Molecular Templates, Inc. (Nasdaq: MTEM, “Molecular Templates” or “MTEM”), a clinical-stage biopharmaceutical...
ADMA Biologics Presents Late-Breaking Poster Presentation Highlighting Clinical Utility of S. Pneumoniae Hyperimmune Globulin at the 2021 American Academy of Allergy, Asthma & Immunology Virtual Annual Meeting
Poster Presentation Highlights the Need for a Polyclonal Hyperimmune Globulin Targeting S. Pneumoniae to Bridge Vaccination and Seroconversion Across Multiple...
Cytokinetics Joins Global Initiative to Recognize International Rare Disease Day
SOUTH SAN FRANCISCO, Calif., Feb. 26, 2021 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that on February 28 it...
Streamline Health Announces Pricing of Upsized $14 Million Public Offering of Common Stock
ATLANTA, GA, Feb. 26, 2021 (GLOBE NEWSWIRE) -- Streamline Health Solutions, Inc. (NASDAQ: STRM) (“Streamline Health”), provider of the eValuator™...
SIGA Technologies to Host Business Update Call on March 4, 2021 Following Release of Year End 2020 Financial Results
NEW YORK, Feb. 26, 2021 (GLOBE NEWSWIRE) -- SIGA Technologies, Inc. (SIGA) (NASDAQ: SIGA), a commercial-stage pharmaceutical company focused on...
Golden Leaf Holdings Enters into Letter of Intent to Acquire Retail Chain
PORTLAND, Ore., Feb. 26, 2021 (GLOBE NEWSWIRE) -- Golden Leaf Holdings Ltd. (CSE: GLH) (OTCQB: GLDFF) (“Golden Leaf,” “GLH” or...
Assembly Biosciences and Arbutus Biopharma Initiate Phase 2 Clinical Trial of Triple Combination Therapy for the Treatment of Chronic Hepatitis B Virus
Trial will evaluate Assembly’s core inhibitor candidate, vebicorvir, with Arbutus’ RNAi therapeutic candidate, AB-729, and standard-of-care NrtI therapy SOUTH SAN...
Crescent European Specialty Lending Announces Refinancing for Leading Contract Research Organization Avania
LONDON & LOS ANGELES--(BUSINESS WIRE)--Crescent Capital Group LP, a leading alternative asset management firm, announced today that its European Specialty...